Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
F13A1 encodes the coagulation factor XIII A subunit. Additionally we are shipping Coagulation Factor XIII, A1 Polypeptide Kits (36) and Coagulation Factor XIII, A1 Polypeptide Proteins (12) and many more products for this protein.
Showing 10 out of 328 products:
Human Monoclonal F13A1 Primary Antibody for ELISA - ABIN396823
Romero, Friel, Velez Edwards, Kusanovic, Hassan, Mazaki-Tovi, Vaisbuch, Kim, Erez, Chaiworapongsa, Pearce, Bartlett, Salisbury, Anant, Vovis, Lee, Gomez, Behnke, Oyarzun, Tromp, Williams, Menon: A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). in American journal of obstetrics and gynecology 2010
Show all 5 references for 396823
Human Polyclonal F13A1 Primary Antibody for ELISA, WB - ABIN238563
Higaki, Nakano, Onaka, Amano, Tanioka, Harada, Hashimoto, Sakaida, Okita: Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease. in Journal of gastroenterology and hepatology 2006
Human Polyclonal F13A1 Primary Antibody for EIA, ID - ABIN113376
Wang, Yang, Ran: Localized papular mucinosis with IgA nephropathy: a case report. in Archives of dermatology 2011
kinetic and structural analysis of interactions between thrombin (show F2 Antibodies) and the Factor XIII (show UGDH Antibodies) activation peptide
These findings provide insight into assembly of the fibrinogen/FXIII-A2B2 complex in both physiologic and therapeutic situations.
FXIIIa exhibits a preference for Q237 in crosslinking reactions within fibrinogen alphaC (233-425) followed by Q328 and Q366.
factor XIII (show UGDH Antibodies) Val34Leu polymorphism is associated with coronary artery diseases risk, especially myocardial infarction. Age and sex did not affect the relationship between factor XIII (show UGDH Antibodies) Val34Leu polymorphism and diseases risk (Meta-Analysis)
Genetic basis of severe factor XIII (show UGDH Antibodies) deficiency in a large cohort of Indian patients has been uncovered.
Mutations in the activation peptide of full-length recombinant FXIII regulate activation rates by thrombin (show F2 Antibodies), and V34L influences in vivo thrombus formation by increased cross-linking of the clot (show TXNDC17 Antibodies).
Report immunochromatographic test for detection of anti-factor XIII (show UGDH Antibodies) A subunit antibodies that can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII (show UGDH Antibodies).
there is an evidence for association between factor XIII (show UGDH Antibodies) Val34Leu polymorphism and CSX (show NKX2-5 Antibodies)
These findings expose a newly recognized, essential role for fibrin crosslinking during whole blood clot (show TXNDC17 Antibodies) formation and consolidation and establish FXIIIa activity as a key determinant of thrombus composition and size.
Results show that FXIII-B Arg95 variant is associated with an increased risk of abdominal aortic aneurysms (AAA (show APP Antibodies)) suggesting a possible role for FXIII in AAA (show APP Antibodies) pathogenesis.
His343Gln was a novel missense mutation occurring in the core domain of the FXIII A subunit. This is the first report of genetically confirmed FXIII deficiency in Korea, with novel and recurrent F13A1 mutations.
Mast cells have the ability to produce and degrade FXIIIA depending on their chymase (show CMA1 Antibodies) expression profile: mast cells expressing chymase (show CMA1 Antibodies) degrade FXIIIA, whereas mast cells that do not express chymase (show CMA1 Antibodies) mainly produce FXIIIA
A lack of factor XIII (show UGDH Antibodies) leads to prolonged clotting times, increased signs of inflammation, and elevated bacterial dissemination in streptococcal skin diseases.
5-HT (show DDC Antibodies) inhibits Factor XIII (show UGDH Antibodies)-A-mediated plasma fibronectin (show FN1 Antibodies) matrix assembly and crosslinking in osteoblast cultures via direct competition with transamidation
High Transglutaminase factor XIII (show UGDH Antibodies) promotes arthritis through mechanisms linked to inflammation and bone erosion.
Fibrinogen from mice harboring the Fibgamma390-396A mutation exhibited reduced binding to FXIII, and plasma from these mice exhibited delayed FXIII activation and fibrin crosslinking, indicating these residues mediate FXIII binding and activation.
FXIII-A serves as a preadipocyte-bound proliferation/differentiation switch that mediates effects of hepatocyte-produced circulating pFN.
Physiological significance of mouse TG2 (show TGM2 Antibodies) and Factor XIII (show UGDH Antibodies) through identification of substrate proteins in MC3T3-E1 cells.
Studies indicate that in FXIII-A-knockout mice, tail-tip bleeding times are doubled and clot (show TXNDC17 Antibodies) stability, assessed by thromboelastography, was impaired compared with wild-type mice.
This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits\; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.
coagulation factor XIII, A1 polypeptide
, blood coagulation factor XIII A1 subunit
, coagulation factor XIII A1 subunit
, coagulation factor XIII A chain
, Coagulation factor XIII A chain
, coagulation factor XIII A chain-like
, FSF, A subunit
, bA525O21.1 (coagulation factor XIII, A1 polypeptide)
, coagulation factor XIII, A polypeptide
, coagulation factor XIIIa
, factor XIIIa
, fibrin stabilizing factor, A subunit
, protein-glutamine gamma-glutamyltransferase A chain
, transglutaminase A chain
, transglutaminase. plasma
, coagulation factor XIII, A1 subunit
, coagulation factor XIIIA
, Factor XIIIA
, coagulation factor XIII, alpha subunit